Advertisement

Digitalis Promotes Ventricular Arrhythmias in Flecainide- and Ranolazine-Pretreated Hearts

  • Christian Ellermann
  • Julian Wolfes
  • Dirk Puckhaber
  • Nils Bögeholz
  • Patrick Leitz
  • Philipp S. Lange
  • Lars Eckardt
  • Gerrit Frommeyer
Article
  • 25 Downloads

Abstract

A post hoc analysis of the PALLAS trial suggested life-threatening interactions of digitalis and dronedarone. Thus, there is concern about an interplay between digitalis and other drugs that influence cardiac electrophysiology. We therefore investigated the interaction between digitalis and flecainide or ranolazine. Twenty-five rabbit hearts were Langendorff-perfused and treated with flecainide (2 µM, 12 hearts) or ranolazine (10 µM, 13 hearts). Infusion of flecainide prolonged mean action potential duration [APD90, from 153 ms (interquartile range (IQR): 29.7 ms) to 159 ms (IQR: 24.9 ms, p = 0.04)] and effective refractory period [ERP, 170 ms (IQR: 40 ms) vs. 200 ms (IQR: 32.5 ms, p < 0.01)]. Administration of ranolazine prolonged APD90 [144 ms (IQR: 34.3 ms)) vs. 157 ms (IQR: 31.2 ms, p < 0.01)] and ERP [180 ms (IQR: 40 ms) vs. 200 ms (IQR: 30 ms, p < 0.01)]. Additional infusion of the digitalis glycoside ouabain (0.2 µM) abbreviated APD90 and ERP in both groups (flecainide: APD90: to 128 ms (IQR: 19 ms), ERP: to 170 ms (IQR: 20 ms), p < 0.01 each; ranolazine: APD90: to 141 ms (IQR: 40 ms), ERP: to 160 ms (IQR: 30 ms), p < 0.01 each). Ventricular vulnerability was assessed by a pacing protocol employing premature extra stimuli and burst stimulation. No proarrhythmic effect was observed with flecainide (1 vs. 3 episodes at baseline) or ranolazine (3 vs. 11 episodes at baseline). However, further infusion of ouabain had a proarrhythmic effect for both drugs (flecainide: 15 episodes, p = 0.04; ranolazine: 21 episodes, p = 0.09). Concomitant treatment of the sodium channel blockers flecainide or ranolazine with digitalis seems to be proarrhythmic. Abbreviation of repolarization and refractoriness that can facilitate re-entry was found as underlying mechanism.

Keywords

Digitalis Flecainide Ranolazine Ventricular arrhythmias Sudden cardiac death 

Notes

Acknowledgements

This study was supported by the Hans-and-Gertie Fischer Foundation and by the German Cardiac Society (to G.F.).

Compliance with Ethical Standards

Conflict of interest

All other authors declare to have no conflict of interest.

Ethical Approval and Statement

All applicable international, national and institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution at which the studies were conducted.

References

  1. 1.
    Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., et al. (2016). 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace, 18(11), 1609–1678.CrossRefPubMedGoogle Scholar
  2. 2.
    Gonano, L. A., Sepúlveda, M., Rico, Y., Kaetzel, M., Valverde, C. A., Dedman, J., et al. (2011). Calcium-Calmodulin Kinase II mediates digitalis-induced arrhythmias. Circulation Arrhythmia Electrophysiology, 4(6), 947–957.CrossRefPubMedGoogle Scholar
  3. 3.
    Ziff, O. J., Kotecha, D.. Digoxin (2016). The good and the bad. Trends in Cardiovascular Medicine, 26(7), 585–595.CrossRefPubMedGoogle Scholar
  4. 4.
    Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G., Coats, A. J., et al. (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal, 37(27), 2129–2200.CrossRefPubMedGoogle Scholar
  5. 5.
    Eisen, A., Ruff, C. T., Braunwald, E., Hamershock, R. A., Lewis, B. S., Hassager, C., et al. (2017). Digoxin use and subsequent clinical outcomes in patients with atrial fibrillation with or without heart failure in the ENGAGE AF-TIMI 48 trial. Journal of the American Heart Association, 6(7), e006035.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Washam, J. B., Stevens, S. R., Lokhnygina, Y., Halperin, J. L., Breithardt, G., Singer, D. E., et al. (2015). Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: A retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). The Lancet, 385(9985), 2363–2370.CrossRefGoogle Scholar
  7. 7.
    Vamos, M., Erath, J. W., & Hohnloser, S. H. (2015). Digoxin-associated mortality: A systematic review and meta-analysis of the literature. European Heart Journal, 36(28), 1831–1838.CrossRefPubMedGoogle Scholar
  8. 8.
    Lopes, R. D., Rordorf, R., De Ferrari, G. M., Leonardi, S., Thomas, L., Wojdyla, D. M., et al. (2018). Digoxin and mortality in patients with atrial fibrillation. Journal of the American College of Cardiology, 71(10), 1063–1074.CrossRefPubMedGoogle Scholar
  9. 9.
    Takahara, A., Sugiyama, A., & Hashimoto, K. (2004). Effects of class I antiarrhythmic drugs on the digitalis-induced triggered activity arrhythmia model: A rationale for the short-term use of class I drugs against triggered arrhythmias. Heart and Vessels, 19(1), 43–48.CrossRefPubMedGoogle Scholar
  10. 10.
    Hohnloser, S. H., Halperin, J. L., Camm, A. J., Gao, P., Radzik, D., & Connolly, S. J. Interaction between digoxin and dronedarone in the PALLAS trial. Circulation: Arrhythmia and Electrophysiology. 2014:7(6), 1019.Google Scholar
  11. 11.
    Frommeyer, G., Milberg, P., Schulze Grotthoff, J., Dechering, D. G., Kochhäuser, S., Stypmann, J., et al. (2015). Dronedarone and digitalis: Individually reduced post-repolarization refractoriness enhances life-threatening arrhythmias. Europace, 17(8), 1300–1308.CrossRefPubMedGoogle Scholar
  12. 12.
    Frommeyer, G., Puckhaber, D., Ellermann, C., Dechering, D. G., Kochhäuser, S., Leitz, P., et al. (2017). Interactions of digitalis and class-III antiarrhythmic drugs: Amiodarone versus dronedarone. International Journal of Cardiology, 228, 74–79.CrossRefPubMedGoogle Scholar
  13. 13.
    Frommeyer, G., Weller, J., Ellermann, C., Bögeholz, N., Leitz, P., Dechering, D. G., et al. (2017). Ivabradine reduces digitalis-induced ventricular arrhythmias. Basic & Clinical Pharmacology & Toxicology, 121(6), 526–530.CrossRefGoogle Scholar
  14. 14.
    Rayner-Hartley, E., & Sedlak, T. (2016). Ranolazine: A contemporary review. Journal of the American Heart Association, 5(3), e003196.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Gupta, T., Khera, S., Kolte, D., Aronow, W. S., & Iwai, S. (2015). Antiarrhythmic properties of ranolazine: A review of the current evidence. International Journal of Cardiology, 187, 66–74.CrossRefPubMedGoogle Scholar
  16. 16.
    Montalescot, G., Sechtem, U., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., et al. (2013). 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. European Heart Journal, 34(38), 2949–3003.CrossRefPubMedGoogle Scholar
  17. 17.
    Reiffel, J. A., Camm, A. J., Belardinelli, L., Zeng, D., Karwatowska-Prokopczuk, E., Olmsted, A., et al. The HARMONY trial: Combined ranolazine and dronedarone in the management of paroxysmal atrial fibrillation: mechanistic and therapeutic synergism. Circulation: Arrhythmia and Electrophysiology. 2015:CIRCEP. 115.002856..Google Scholar
  18. 18.
    Bunch, T. J., Mahapatra, S., Murdock, D., Molden, J., Weiss, J. P., May, H. T., et al. (2011). Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks. Pacing and Clinical Electrophysiology, 34(12), 1600–1606.CrossRefPubMedGoogle Scholar
  19. 19.
    Frommeyer, G., Milberg, P., Uphaus, T., Kaiser, D., Kaese, S., Breithardt, G., et al. (2013). Antiarrhythmic effect of ranolazine in combination with class III drugs in an experimental whole-heart model of atrial fibrillation. Cardiovascular Therapeutics, 31(6), e63–e71.  https://doi.org/10.1111/1755-5922.12035.CrossRefPubMedGoogle Scholar
  20. 20.
    Frommeyer, G., Ellermann, C., Dechering, D. G., Kochhäuser, S., Bögeholz, N., Güner, F., et al. (2016). Ranolazine and vernakalant prevent ventricular arrhythmias in an experimental whole-heart model of short QT syndrome. Journal of Cardiovascular Electrophysiology, 27(10), 1214–1219.CrossRefPubMedGoogle Scholar
  21. 21.
    Ellermann, C., Wolfes, J., Kochhäuser, S., Dechering, D. G., Reinke, F., Wasmer, K., et al. (2017). Divergent antiarrhythmic effects of resveratrol and piceatannol in a whole-heart model of long QT syndrome. International Journal of Cardiology, 243, 233–238.CrossRefPubMedGoogle Scholar
  22. 22.
    Frommeyer, G., Sterneberg, M., Dechering, D. G., Kaese, S., Bögeholz, N., Pott, C., et al. (2017). Effective suppression of atrial fibrillation by the antihistaminic agent antazoline: First experimental insights into a novel antiarrhythmic agent. Cardiovascular Therapeutics, 35(2), e12244.CrossRefGoogle Scholar
  23. 23.
    Frommeyer, G., Kaiser, D., Uphaus, T., Kaese, S., Osada, N., Rajamani, S., et al. (2012). Effect of ranolazine on ventricular repolarization in class III antiarrhythmic drug-treated rabbits. Heart Rhythm, 9(12), 2051–2058.CrossRefPubMedGoogle Scholar
  24. 24.
    Morgan, E. E., Li, Z., Stebal, C., Belliard, A., Tennyson, G., Salari, B., et al. (2010). Preconditioning by sub-inotropic doses of ouabain in the Langendorff-perfused rabbit heart. Journal of Cardiovascular Pharmacology, 55(3), 234.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Ellermann, C., Sterneberg, M., Kochhäuser, S., Dechering, D. G., Fehr, M., Eckardt, L., et al. (2018). Antiarrhythmic effect of antazoline in experimental models of acquired short-and long-QT-syndromes. Europace, 20(10), 1699–1706.CrossRefPubMedGoogle Scholar
  26. 26.
    Lewis, G. P., & Holtzman, J. L. (1984). Interaction of flecainide with digoxin and propranolol. American Journal of Cardiology, 53(5), B52–B57.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Cardiology II – ElectrophysiologyUniversity Hospital MünsterMünsterGermany
  2. 2.Klinik für Kardiologie II – RhythmologieUniversitätsklinikum MünsterMünsterGermany

Personalised recommendations